Results 221 to 230 of about 6,670,626 (362)
Proteomic and phosphoproteomic analyses were performed on lung adenocarcinoma (LUAD) tumors with EGFR, KRAS, or EML4–ALK alterations and wild‐type cases. Distinct protein expression and phosphorylation patterns were identified, especially in EGFR‐mutated tumors. Key altered pathways included vesicle transport and RNA splicing.
Fanni Bugyi+12 more
wiley +1 more source
Letter to the Editor commenting on “Solid Waste Disposal—Facts versus Fiction” (Alvarez, Ronald J., 1976, Mechanical Engineering) [PDF]
G. C. Wiedersum
openalex +1 more source
Targeting of PTP4A3 overexpression sensitises HGSOC cells towards chemotherapeutic drugs
In HGSOC with normal KRAS expression, high PTP4A3 expression regulates autophagy activation. Conversely, in HGSOC with high KRAS expression, KRAS dictates autophagy control, and PTP4A3 is not required. When high PTP4A3 expression is inhibited, HGSOC cells are preferentially sensitised towards DNA‐damaging agents.
Ana López‐Garza+3 more
wiley +1 more source
Screening 166 FDA‐approved anticancer drugs identifies the aromatase inhibitor Exemestane as a synergistic partner of PARP inhibitor Olaparib in BRCA‐proficient triple‐negative breast cancer. Exemestane induces ROS‐mediated replication stress, enhancing DNA damage and apoptosis alongside Olaparib.
Nur Aininie Yusoh+5 more
wiley +1 more source
The constant volume heat capacities of gaseous trifluoromethane, chlorodifluoromethane, and dichlorofluoromethane : a dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the University of Michigan Department of Chemical and Mechanical Engineering [PDF]
Pratip Bandyopadhyay
openalex
Wire-wrap assembly engineering. Phase I. Mechanical test results. [LMFBR]
Sibel Kaplan
openalex +2 more sources
RKIP, a metastasis suppressor protein, modulates key oncogenic pathways in lung adenocarcinoma. In silico analyses linked low RKIP expression to poor survival. Functional studies revealed RKIP overexpression reduces tumor aggressiveness and enhances sensitivity to EGFR‐targeted therapies, while its loss promotes resistance.
Ana Raquel‐Cunha+10 more
wiley +1 more source